Warner Chilcott Reports Operating Results for the Quarter Ended Septembe...(d cash net income for all periods are pr...),Health
d cash net income for all periods are presented in the table at the end of this press release.
Revenue
Revenue in the quarter ended September 30, 2007 was $226.5 million, an increase of $31.8 million, or 16.3%, over the same quarter in the prior year. The primary drivers of the increase in revenue as compared to the prior year quarter were the net sales of two products introduced in March 2006, LOESTRIN 24 FE and TACLONEX.
Sales of our oral contraceptive products increased $8.8 million, or
14.4%, in the quarter ended September 30, 2007, compared with the prior
year quarter. We began commercial sales of LOESTRIN 24 FE in March 2006 and
launched promotional efforts behind the product in April 2006. LOESTRIN 24
FE generated revenue of $38.2 million in the quarter ended September 30,
2007, compared to $15.1 million in the prior year quarter. Filled
prescriptions of LOESTRIN 24 FE increased 9.8% sequentially in the quarter
ended September 30, 2007 compared to the quarter ended June 30, 2007. We
introduced and began commercial sales of FEMCON FE in the second half of
2006, but did not initiate promotional efforts in support of the product
until April 2007. FEMCON FE is a promotional priority for our Chilcott
sales force and generated revenues of $9.4 million in the quarter ended
September 30, 2007. Filled prescriptions of FEMCON FE increased 30.5%
sequentially in the quarter ended September 30, 2007 compared to the
quarter ended June 30, 2007. Net sales of ESTROSTEP decreased $7.6 million,
or 29.5%, in the quarter ended September 30, 2007 compared to the prior
year quarter. The decrease in ESTROSTEP net sales was primarily due to the
shift of our promotional efforts away from this product beginning in April
2006 resulting in a 38.0% decline in filled prescriptions for the quarter
ended September 30, 2007 compared with the same quarter in 2006. A portion
of the reduced demand was offset by higher selling prices in the current
quarter. The Company believes
'/>"/>
| SOURCE Warner Chilcott Limited Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
2. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |